Escitalopram and Dabigatran Etexilate: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Escitalopram
Dabigatran Etexilate
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
An increased risk of bleeding
Interaction Deep Dive
The release of serotonin by platelets is important for maintaining hemostasis. Case-control and cohort studies have shown combined use of SSRIs and anticoagulants to be associated with an increased risk of bleeding213, including an 18.85-fold increased risk of major bleeding with concomitant use of escitalopram with full-dose enoxaparin in a retrospective cohort of adults with acute VTE. Bleeding events reported have included epistaxis, ecchymosis, hematoma, petechiae, and life-threatening hemorrhages. Altered anticoagulant effects (including increased bleeding) have been reported with the coadministration of SSRIs with warfarin 13.
Why it happens (mechanism)
Additive effects on hemostasis; a reduction in 5-HT–mediated platelet aggregation caused by escitalopram
Literature reports
3 reports — tap to read
a) Concomitant use of escitalopram and full-dose enoxaparin resulted in an 18.85-fold increased risk of major bleeding compared with any of the other SSRIs or in patients not on SSRI therapy (46.2% vs 15.2% and 17.0%) in a retrospective cohort study in adults with primary or secondary acute VTE, including pulmonary embolism or DVT treated with an SSRI plus enoxaparin (n=483) or with enoxaparin only (n=92) 4.
b) According to a retrospective cohort study (n=234), there was an increased risk of clinically relevant bleeding (hospital admission due to bleeding) in patients receiving warfarin for atrial fibrillation during concomitant SSRI therapy or within 2 weeks following SSRI therapy termination. Patients with a mean age of 72 +/- 7 years receiving warfarin plus SSRI (n=117) were matched with randomly selected patients who received warfarin only (n=117). SSRI included fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, or escitalopram. Nine patients experienced 11 bleeding episodes during 213.9 treatment years in the warfarin plus SSRI group, and 10 patients experienced 14 bleedings during 586.4 treatment years in the warfarin-only group. The corresponding total incidences of bleedings were 51.4 and 23.9 per 1000 treatment years, respectively. The hazard ratio for first bleedings during treatment with warfarin plus SSRI was 3.49 (95% CI; 1.37 to 8.91, p=0.009) compared with warfarin only. The SSRI implicated in patients experiencing bleeding at the time of concomitant administration were sertraline or citalopram. The addition of an SSRI was not associated with a change in warfarin dose or INR (p=0.48 and p=0.31 respectively). The results of the study may be limited by earlier bleeding events, unknown patient adherence, and exclusion of clopidogrel, dipyridamol, corticosteroids and anticoagulants other than warfarin in the model 2.
c) A population-based, case-controlled study of new coumarin users (acenocoumarol and phenprocoumon) with concomitant selective serotonin reuptake inhibitors (SSRIs) resulted in an increased risk of hospitalization due to non-gastrointestinal bleeding. Using national pharmacy and hospitalization records, Netherlands researchers identified 1848 cases that were admitted for abnormal bleeding and compared them with 5818 control subjects also taking coumarins. Median duration of treatment in patients was 220 days (range, 1 to 4690 days). Patients on SSRIs showed greater risk for hospitalization for non-gastrointestinal bleeding (adjusted odds ratio (OR) 1.7, 95% confidence interval (CI), 1.1 to 2.5), however, the rate of gastrointestinal bleeding (adjusted OR 0.8, 95% CI, 0.4 to 1.5) was not significantly different 1.
Common questions
Can I take Escitalopram and Dabigatran Etexilate together?
An increased risk of bleeding Always confirm with your pharmacist or prescriber before making any change.
How serious is the Escitalopram and Dabigatran Etexilate interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Escitalopram or Dabigatran Etexilate need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Schalekamp T, Klungel OH, Souverein PC, et al: Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168(2):180-185. PubMed
- Wallerstedt SM, Gleerup H, Sundstrom A, et al: Risk of clinically relevant bleeding in warfarin-treated patients-influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18(5):412-416. PubMed
- Product Information: LEXAPRO(R) oral tablets, oral solution, escitalopram oral tablets, oral solution. Abbvie, Inc (per FDA), North Chicago, IL, 2023. DailyMed
- Samuel NG & Seifert CF: Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. Ann Pharmacother 2017; 51(3):226-231. PubMed
Keep reading about Escitalopram
Keep reading about Dabigatran Etexilate
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist